Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

11/12/24 10:34:18 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $RXRX alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 RECURSION PHARMACEUTICALS INC CLASS A COMMON STOCK Cusip #75629V104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #75629V104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 8,359,174 Item 6: 0 Item 7: 8,363,529 Item 8: 0 Item 9: 8,363,529 Item 11: 3.040% Item 12: HC Cusip #75629V104 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 8,363,529 Item 8: 0 Item 9: 8,363,529 Item 11: 3.040% Item 12: IN Item 1(a). Name of Issuer: RECURSION PHARMACEUTICALS INC Item 1(b). Address of Issuer's Principal Executive Offices: 41S RIO GRANDE STREET SALT LAKE CITY, UT 84101 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: CLASS A COMMON STOCK Item 2(e). CUSIP Number: 75629V104 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 8,363,529 (b) Percent of Class: 3.040% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 8,363,529 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the CLASS A COMMON STOCK of RECURSION PHARMACEUTICALS INC. No one other person's interest in the CLASS A COMMON STOCK of RECURSION PHARMACEUTICALS INC is more than five percent of the total outstanding CLASS A COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the CLASS A COMMON STOCK of RECURSION PHARMACEUTICALS INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $RXRX alert in real time by email

Recent Analyst Ratings for

$RXRX

Date	Price Target	Rating	Analyst
7/3/2025	$5.00	Equal-Weight	Morgan Stanley
5/22/2023	$8.00	Equal-Weight	Morgan Stanley
3/16/2023	$17.00	Buy	Needham
9/16/2022	$20.00	Overweight	KeyBanc Capital Markets
4/18/2022	$10.00	Buy → Neutral	BofA Securities
3/4/2022	$32.00 → $10.00	Outperform → Market Perform	SVB Leerink
12/8/2021	$30.00 → $32.00	Outperform	SVB Leerink
9/21/2021	$37.00	Buy	Berenberg

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

11/12/24 10:34:18 AM ET

$RXRX

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $RXRX alert in real time by email

Recent Analyst Ratings for

$RXRX

Date	Price Target	Rating	Analyst
7/3/2025	$5.00	Equal-Weight	Morgan Stanley
5/22/2023	$8.00	Equal-Weight	Morgan Stanley
3/16/2023	$17.00	Buy	Needham
9/16/2022	$20.00	Overweight	KeyBanc Capital Markets
4/18/2022	$10.00	Buy → Neutral	BofA Securities
3/4/2022	$32.00 → $10.00	Outperform → Market Perform	SVB Leerink
12/8/2021	$30.00 → $32.00	Outperform	SVB Leerink
9/21/2021	$37.00	Buy	Berenberg

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$RXRX

Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$RXRX

$RXRX
SEC Filings

SEC Form 10-Q filed by Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

Recursion Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Unregistered Sales of Equity Securities

$RXRX
Insider Trading

Chief Executive Officer Gibson Christopher converted options into 541,541 shares, sold $3,263,964 worth of shares (618,175 units at $5.28) and gifted 10,000 shares, decreasing direct ownership by 8% to 994,619 units (SEC Form 4)

Director Li Dean Y was granted 1,949 shares, increasing direct ownership by 0.16% to 1,236,567 units (SEC Form 4)

Director Dar Zavain was granted 2,924 shares, increasing direct ownership by 2% to 135,817 units (SEC Form 4)

$RXRX
Press Releases

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

$RXRX
Analyst Ratings

Morgan Stanley resumed coverage on Recursion Pharmaceuticals with a new price target

Morgan Stanley initiated coverage on Recursion Pharmaceuticals with a new price target

Needham initiated coverage on Recursion Pharmaceuticals with a new price target

$RXRX
Leadership Updates

Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

Altitude Lab Startups Raise $154M in Capital

Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer

$RXRX
Financials

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

$RXRX
Large Ownership Changes